244 related articles for article (PubMed ID: 11918852)
1. Effects of reactive oxygen species on lymphokine-activated killer cells in patients with bladder cancer.
Wang ZP; Chen YR; Zheng RL; Lu JZ; Wang JJ
Acta Pharmacol Sin; 2002 Mar; 23(3):257-62. PubMed ID: 11918852
[TBL] [Abstract][Full Text] [Related]
2. Modulating effect of mitomycin or cisplatin on lymphokine-activated killer cell proliferation and antitumor activity to bladder cancer cell lines in vitro.
Wang ZP; Qing DS; Shi BG; Chen YR; Liu GD
Zhongguo Yao Li Xue Bao; 1998 Jul; 19(4):369-72. PubMed ID: 10375787
[TBL] [Abstract][Full Text] [Related]
3. Effect of TNF-alpha and IFN-alpha on the proliferation and cytotoxicity of lymphokine-activated killer cells in patients with bladder cancer.
Wang Z; Cheng Y; Zheng R; Qin D; Liu G
Chin Med J (Engl); 1997 Mar; 110(3):180-3. PubMed ID: 9594335
[TBL] [Abstract][Full Text] [Related]
4. Tretinoin or retinol enhancement of lymphokine-activated killer cell proliferation and cytotoxicity against human bladder cancer cells in vitro.
Wang ZP; Zheng RL; Chen YR; Liu GD
Zhongguo Yao Li Xue Bao; 1997 Nov; 18(6):522-4. PubMed ID: 10322910
[TBL] [Abstract][Full Text] [Related]
5. Basic fibroblast growth factor enhanced LAK cell cytotoxicities against human bladder neoplasm cells.
Wang ZP; Duan GL; Chen YR; Qin DS; Liu GD; Niu HG
Zhongguo Yao Li Xue Bao; 1999 Mar; 20(3):276-8. PubMed ID: 10452107
[TBL] [Abstract][Full Text] [Related]
6. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
Hermann GG; Zeuthen J; Claësson MH
Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
[TBL] [Abstract][Full Text] [Related]
7. In vitro effects of prostaglandin E2 or indomethacin on the proliferation of lymphokine-activated killer cells and their cytotoxicity against bladder tumor cells in patients with bladder cancer.
Wang Z; Chen Y; Zheng R; Qin D; Chen X; Wang Y; Liu G
Prostaglandins; 1997 Nov; 54(5):769-79. PubMed ID: 9491207
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of murine lymphokine-activated killer cell activity by retinoic acid.
Lin TH; Chu TM
Cancer Res; 1990 May; 50(10):3013-8. PubMed ID: 1970751
[TBL] [Abstract][Full Text] [Related]
10. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
Kasid A; Bell GI; Director EP
J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
[TBL] [Abstract][Full Text] [Related]
11. Effects of N(G)-Nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, on IL-2-induced LAK cell generation in vivo and in vitro in healthy and tumor-bearing mice.
Orucevic A; Lala PK
Cell Immunol; 1996 Apr; 169(1):125-32. PubMed ID: 8612285
[TBL] [Abstract][Full Text] [Related]
12. The role of lymphotoxin in the IL-2-driven differentiation of human lymphokine-activated T-killer (T-LAK) cells in vitro.
Abe Y; Van Eden M; Gatanaga M; Wang FI; Brightbill HD; Granger GA; Gatanaga T
Lymphokine Cytokine Res; 1993 Oct; 12(5):279-83. PubMed ID: 8260536
[TBL] [Abstract][Full Text] [Related]
13. [The effect of MPS on LAK cell growth and its cytotoxic activity against laryngeal cancer (HEP-2)].
Wang J; Zhu X; Chen J
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1996; 31(5):283-6. PubMed ID: 9642362
[TBL] [Abstract][Full Text] [Related]
14. Generation of lymphokine-activated killer activity in rodents but not in humans is nitric oxide dependent.
Juretic A; Spagnoli GC; von Bremen K; Hörig H; Filgueira L; Lüscher U; Babst R; Harder F; Heberer M
Cell Immunol; 1994 Sep; 157(2):462-77. PubMed ID: 8069927
[TBL] [Abstract][Full Text] [Related]
15. Sequential TNF and TGF-beta regulation of expansion and induction of cytotoxicity in long-term cultures of lymphokine-activated killer cells.
Koberda J; Przepiorka D; Moser RP; Grimm EE
Lymphokine Cytokine Res; 1994 Apr; 13(2):139-45. PubMed ID: 8061115
[TBL] [Abstract][Full Text] [Related]
16. LAK cell mediated apoptosis of human bladder cancer cells involves a pH-dependent endonuclease system in the cancer cell: possible mechanism of BCG therapy.
Shemtov MM; Cheng DL; Kong L; Shu WP; Sassaroli M; Droller MJ; Liu BC
J Urol; 1995 Jul; 154(1):269-74. PubMed ID: 7776443
[TBL] [Abstract][Full Text] [Related]
17. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients.
Provinciali M; Di Stefano G; Stronati S; Fabris N
Cytokine; 1998 Feb; 10(2):132-9. PubMed ID: 9512903
[TBL] [Abstract][Full Text] [Related]
18. Ability of lymphokine-activated killer cells to lyse mycobacteria-infected cells.
Chiplunkar SV; Deshmukh MA; Kode JA; Gangal SG; Deo MG
Acta Leprol; 1997; 10(4):203-8. PubMed ID: 9447253
[TBL] [Abstract][Full Text] [Related]
19. Lymphokine-activated killer cells can kill target cells not only by early killing but also by late killing, and the late killing level against autotumor cell line.
Komatsu F; Ishiguro K
Oncol Res; 2003; 13(4):235-41. PubMed ID: 12659424
[TBL] [Abstract][Full Text] [Related]
20. Fibrin coating of bladder tumor cells (T24) is not protective against LAK cell cytotoxicity.
Carr ME; Sajer SA; Spaulding A
J Lab Clin Med; 1992 Feb; 119(2):132-8. PubMed ID: 1740625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
